Used in targeted cancer therapy, particularly for tumors with the KRAS G12C mutation, such as non-small cell lung cancer. It works by selectively binding to the inactive form of the mutant KRAS protein, locking it in an off state and preventing downstream signaling pathways that drive cell proliferation. This inhibition leads to reduced tumor growth and can induce tumor regression in responsive patients. It is designed for oral administration and shows improved potency and pharmacokinetic properties over earlier inhibitors, making it suitable for clinical use in precision oncology.